個股熱度排行 | 6月2日港股盤前
根據uSMART輿情監測數據,從1日晚間到2日港股盤前時間段,市場關注指數最高的4只股票是蔚來-SW、歐康維視生物-B、福萊特玻璃、創勝集團-B。
6月2日—港股關注排行TOP4

蔚來-SW

關注度第一爲蔚來-SW,該股上個交易日收盤上漲2.35%,報於139.20港元。近5個交易日累計上漲17.47%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
造車新勢力5月交付量呈膠着狀態:理想上演“天地板” 蔚來供應鏈加速恢復中
蔚來5月交付新車7,024臺 同比環比雙增長
歐康維視生物-B

關注度第二爲歐康維視生物-B,該股上個交易日收盤下跌8.70%,報於10.70港元。近5個交易日累計下跌4.46%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
歐康維視生物-B附屬與暉致中國訂立愛賽平推廣協議
歐康維視生物簽訂滴眼液內地推廣協議
福萊特玻璃

關注度第三爲福萊特玻璃,該股上個交易日收盤下跌3.22%,報於31.60港元。近5個交易日累計上漲0.96%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
福萊特玻璃擬非公開發行A股不超5.09億股 募資不超60億元
福萊特玻璃增發H股批覆到期失效
創勝集團-B

關注度第四爲創勝集團-B,該股上個交易日收盤下跌0.21%,報於4.77港元。近5個交易日累計下跌2.25%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
創勝集團在ASCO 2022上公佈TST001聯合CAPOX作爲晚期及轉移性胃癌/胃食管連接部癌一線治療的I期臨牀數據
創勝集團-B:在2022年ASCO上公佈TST001聯合CAPOX作爲晚期及轉移性胃癌╱胃食管連接部癌一線治療的I期臨牀數據
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.